Abstract
A versatile system has been developed, which is capable of transferring genes of interest into a wide variety of mammalian host cells and offers a number of advantages over the other methods for production of antibodies. These advantages include; (1) Shorter timelines, (2) Improved consistency, (3) Higher specific productivities, (4) Better genetic stabilities, (5) Increased flexibility and (6) Ability to work on any cell line.
The GPEx® method utilizes replication defective retroviral vectors, derived from Moloney Murine Leukemia virus (MLV) and pseudotyped with Vesicular Stomatitis Virus Glycoprotein (VSV-G), to stably insert single copies of genes at multiple genomic locations into dividing cells. Retrovectors deliver genes coded as RNA that, after entering the cell, are reverse transcribed to DNA and integrated stably into the genome of the host cell. Two enzymes, reverse transcriptase and integrase, provided transiently in the vector particle, perform this function. These integrated genes are maintained through subsequent cell divisions as if they were endogenous cellular genes. By controlling the number of retrovector particles accessing the cell, multiple gene insertion (desirable for high yielding cell cultures) can be achieved without any of the traditional amplification steps. This chapter describes the use of the GPEx® technology for transferring genes into Chinese Hamster Ovary (CHO) cells, for the purpose of consistently producing cell lines with high antibody production levels in a short amount of time (Fig. 4-1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andrake MD, Skalka AM (1996) Retroviral integrase, putting the pieces together. J Biol Chem 271(33):19633–19636
Barnes LM, Bentley CM, Dickson AJ (2004) Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cells. Biotechnol Bioeng 85(2):115–121
Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993) Vesicular stomatitis virus G glycoprotein-pseudotyped retroviral vectors: concentration to a very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90:8033–8037
Kim NS, Kim SJ, Lee GM (1998) Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selection pressure. Biotechnol Bioeng 60(6):679–688
Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD (2004) Retroviral DNA, integration: ASLV, HIV and MLV show distinct target site preferences. PLoS Biol 2(8):1127–1137
Pear W (1996) Transient transfection methods for preparation of high-titer retroviral supernatants. In: Current protocols in molecular biology, vol 2, edited by Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Wiley, New York, 9.11.1–9.11.18
Schlegel R, Tralka TS, Willingham MC, Pastan I (1983) Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 32:639–646
Strutzenberger K, Borth N, Kunert R, Steinfellner W, Katinger H (1999) Changes during subclone development and ageing of human antibody-producing recombinant CHO cells. J Biotechnol 69:215–226
Wu X, Li Y, Crise B, Burgess SM (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300:1749–1751
Yee JK, Friedmann T, Burns JC (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43:99–112
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Bleck, G.T. (2010). GPEx® A Flexible Method for the Rapid Generation of Stable, High Expressing, Antibody Producing Mammalian Cell Lines. In: Shire, S., Gombotz, W., Bechtold-Peters, K., Andya, J. (eds) Current Trends in Monoclonal Antibody Development and Manufacturing. Biotechnology: Pharmaceutical Aspects, vol XI. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76643-0_4
Download citation
DOI: https://doi.org/10.1007/978-0-387-76643-0_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-76642-3
Online ISBN: 978-0-387-76643-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)